Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

Phase 2CompletedNCT00266526

Allergopharma GmbH & Co. KG

Overview

Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Birch Pollen Allergy

Interventions

Recombinant birch pollenBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Positive RAST result to birch pollen * Positive Skin Prick Test reaction to birch pollen * positive nasal provocation test result to birch pollen extract Exclusion Criteria: * serious chronic diseases * other relevant seasonal allergies

Locations (1)

Allergopharma GmbH & Co. KG

Reinbek, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.